Established Clinical Use of Octreotide and Lanreotide in Oncology

Publisher： Karger

E-ISSN： 1421-9794|47|2|40-53

ISSN： 0009-3157

Source： Chemotherapy, Vol.47, Iss.2, 2001-03, pp. : 40-53

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacogenomics in Pediatric Oncology: Review of Gene—Drug Associations for Clinical Use †

By Mlakar Vid   Huezo-Diaz Curtis Patricia   Satyanarayana Uppugunduri Chakradhara Rao   Krajinovic Maja   Ansari Marc  

International Journal of Molecular Sciences, Vol. 17, Iss. 9, 2016-09 ,pp. : 1502-1502

MDPI

Access to resources Recommend Favorite

Rifaximin, a Peculiar Rifamycin Derivative: Established and Potential Clinical Use Outside the Gastrointestinal Tract

By  

Chemotherapy, Vol. 51, Iss. 1, 2005-04 ,pp. : 122-130

Karger

Access to resources Recommend Favorite

Ensuring Appropriate Use of High Cost Drugs: Octreotide

By  

The Australian Journal of Hospital Pharmacy, Vol. 27, Iss. 3, 1997-06 ,pp. : 250-250

John Wiley & Sons Inc

Access to resources Recommend Favorite

Re-Use of Established Drugs for Anti-Metastatic Indications

By Entschladen Frank   Thyssen Dane A.   Drell David W.  

Cells, Vol. 5, Iss. 1, 2016-01 ,pp. : 2-2

MDPI

Access to resources Recommend Favorite

Next-Generation Sequencing in Clinical Oncology: Next Steps Towards Clinical Validation

By Bennett Nigel C.   Farah Camile S.  

Cancers, Vol. 6, Iss. 4, 2014-11 ,pp. : 2296-2312

MDPI

Access to resources Recommend Favorite